BDBM572180 (rac)-4-chloro-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-1-methyl-1,10,11,12,13,15-hexahydropyrazolo[4′,3′:9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic Acid::US11447504, Example 33::US11478451, Example 35

SMILES CCc1nn(C)c2COCCCCn3c(C(O)=O)c(CCCOc4cccc5cc(F)ccc45)c4ccc(Cl)c(-c12)c34

InChI Key InChIKey=VDWYPXRLOOMXTJ-UHFFFAOYSA-N

Data  9 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 9 hits for monomerid = 572180   

LigandPNGBDBM572180(US11478451, Example 35 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 1.70nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572180(US11478451, Example 35 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 1.70nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/20/2022
Entry Details
US Patent

LigandPNGBDBM572180(US11478451, Example 35 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 22nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572180(US11478451, Example 35 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 1.20E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572180(US11478451, Example 35 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 1.60E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572180(US11478451, Example 35 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 1.80E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572180(US11478451, Example 35 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

TargetBcl-2-like protein 1 [1-212]/Bad BH3 Peptide(Human)
Bayer Aktiengesellschaft

US Patent
LigandPNGBDBM572180(US11478451, Example 35 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572180(US11478451, Example 35 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent